Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 4 2000
Play
Audio Below:
We
published the first, you know, large, I’ll say well designed
placebo controlled trial looking at that, and saw nothing at all.
If you then go and look at the pilot studies, and look pretty carefully,
there is not a whole lot there, there is not a whole lot there.
They say about…there is a significant reduction in hot flashes,
compared to baseline, compared to what they saw with soy. Well,
we’ve shown that there is about a 25% reduction with placebo,
and they weren’t talking about a whole lot more than that.
Now there have been a couple of other placebo controlled trials
out there, and some of them reported a little bit of benefit, but
the amount of benefit is small and even the soy group of promoters
are admitting now that whatever they are seeing is not very much
there. So, hopefully, we’ll sort things out. We’ve talked
to some of the other groups who have published things to try to
do a meta-analysis to look together. There are a lot of different
soy preparations. We went out there, got Archer’s Daniel Midland,
had them do a tablet form instead of having people drink soy milk
– we didn’t think they would tolerate that as well –
and maybe the preparation we chose was not ideal. So maybe there
is another soy product that works, but it remains to be proven of
that and I think the end result is going to be that there is really
not much there, but there might be another product that might do
something.
Biopsy
confirmed benign breast disease, postmenopausal use of exogenous
female hormones, and breast carcinoma risk. Byrne,
C.; Connolly, J. L.; Colditz, G. A., and Schnitt, S. J.. Cancer.
89(10):2046-2052, 2000 Nov 15.
Postmenopausal
estrogens - Opposed, unopposed, or none of the above Willett, W. C.; Colditz, G., and Stampfer, M. (Reprint available
from: Willett WC Harvard Univ, Sch Publ Hlth, Dept Nutr 667 Huntington
Ave Boston, MA 02115 USA).. Jama: Journal of the American Medical
Association. 283(4):534-535, 2000 Jan 26. No abstract
Re:
Effect of hormone replacement therapy on breast cancer risk: Estrogen
versus estrogen plus progestin Archer, D. F.; Bush, T., and Nachtigall, L. E. (Reprint available
from: Nachtigall LE NYU, Sch Med, Dept Obstet & Gynecol 251
E 33rd St New York, NY 10016 USA).. Journal of the National Cancer
Institute. 92(23):1950-1951, 2000 Dec 6. No abstract
Estrogen
deficiency: In search of symptom control and sexuality. Loprinzi, C. L. and Barton, D. Journal of the National Cancer
Institute. 92(13):1028-1029, 2000 Jul 5. No abstract
